Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed on July 9, 2018, by Cellect Biotechnology Ltd., a foreign private issuer based in Kfar Saba, Israel. The filing reports a strategic corporate development involving Cellect Biotherapeutics Ltd., a wholly owned subsidiary of the registrant.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data for the period. The only specific financial figures disclosed relate to the new manufacturing agreement:
- Upfront Payment: Approximately $150,000 payable to Swiss Biotech Center SA (SBC).
- Contingent Payment: Up to an additional $300,000 upon meeting certain conditions.
Information regarding total debt, liquidity, or other balance sheet metrics is not provided in this text.
Material Changes
The primary material change is the execution of a Strategic Manufacturing and Supply Agreement with Swiss Biotech Center SA (SBC). Key terms include:
- Scope: SBC will manufacture FasL protein, the main active ingredient in Cellect's ApoGraft process and Apotainer selection kit.
- Exclusivity: SBC granted Cellect exclusivity to the FasL protein for five years, subject to early termination conditions.
- Duration: The agreement term is ten years, extendable by mutual written agreement.
- Production: SBC is responsible for producing clinical batches of the FasL protein.
Outlook, Risks, and Contingencies
Management commentary indicates a strategic move to secure the supply chain for clinical development. The agreement includes specific termination rights for Cellect if:
- Regulatory approval is not obtained.
- SBC is unable to establish the requisite manufacturing process.
The agreement contains customary representations, warranties, and indemnification provisions. No specific guidance on future revenue or earnings was provided in this filing.
Investor Verification Checklist
- Verify the total cash impact of the $150,000 upfront payment and the specific conditions triggering the $300,000 contingent payment.
- Confirm the status of FasL protein clinical trials and the timeline for regulatory approval, which serves as a termination trigger.
- Review the full text of Exhibit 99.1 (Press Release) for additional details on the strategic rationale.
- Check subsequent filings for updates on SBC's ability to establish the manufacturing process.